Daewoong (003090) Fundamentals 2026 — P/E 3.3x, Revenue Analysis | SniperIQ
Daewoong (003090) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩667.5B, trading at ₩15880.00 on the KSC. This SniperIQ fundamentals page covers Daewoong's valuation (P/E 3.3x, P/B 0.5x), profitability (net margin 8.9%), revenue (₩2.07T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daewoong's market cap?
Daewoong (003090) has a market capitalization of approximately ₩667.5B, trading at ₩15880.00 on the KSC. Market cap moves with the live share price.
What is Daewoong's P/E ratio?
Daewoong's trailing twelve-month P/E ratio is 3.3x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daewoong?
Daewoong runs a net profit margin of 8.9%, a gross margin of 52.8%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daewoong generate?
Daewoong reported revenue of ₩2.07T for fiscal year 2025, with net income of ₩175.1B and earnings per share (EPS) of 4280. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daewoong pay a dividend?
Daewoong offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daewoong financially healthy?
Daewoong carries a debt-to-equity ratio of 0.76x and a current ratio of 1.20x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daewoong a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daewoong (003090) the key facts are: market cap ₩667.5B, P/E 3.3x, revenue ₩2.07T, 52-week range 15650-30600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daewoong's full fundamentals live
Get Daewoong's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.